tbuckley/cabot-search huggingface dataset:
Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
Authors: Andrew W. Roberts, Stephan Stilgenbauer, John F. Seymour, David C.S. Huang
Journal: Clinical Cancer Research (2017)

Venetoclax is the first BCL2 inhibitor to enter routine clinical practice. It is an orally bioavailable small molecule that binds BCL2 very specifically. Acting as a pharmacologic mimic of the proteins that initiate apoptosis (a so-called BH3 mimetic), venetoclax rapidly induces apoptosis in chronic lymphocytic leukemia (CLL) cells, which express high levels of BCL2 and rely on it to maintain their survival. As a single agent, daily venetoclax treatment induced durable responses in 79% of patients with relapsed or refractory CLL or small lymphocytic lymphoma in a phase I study, including complete remissions in 20% of patients. Its use was approved by the FDA in April 2016 for patients with previously treated del(17p) CLL on the basis of a single-arm phase II trial demonstrating a 79% response rate and an estimated 1-year progression-free survival of 72% with 400 mg/day continuous therapy. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data and seeks to place it in the context of rapid advances in therapy for patients with relapsed CLL, especially those with del(17p) CLL. Clin Cancer Res; 23(16); 4527-33. ©2017 AACR.
Addition of Absolute Lymphocytes/Monocytes Ratio Improves the Revised-International Prognostic Index (R-IPI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP
Authors: Leyre Bento, Antonia María Bautista-Gili, Francesc García, Jordi Martínez-Serra, Lucía García-Mañó, Marta García-Recio, Carmen Ballester, Jordi Ginés, Paloma López, Jaime Daumal, Rafael Ramos, Antonio Salar, Antonia Sampol, Juan Besalduch, Antonio Gutiérrez
Journal: Blood (2015)
Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML)
Authors: Rizwan Romee, Rosario Maximillian, Melissa M Berrien-Elliott, Julia A Wagner, Brea A Jewell, Timothy Schappe, Jeffrey W Leong, Stephanie E Schneider, Sarah Willey, Todd A Fehniger
Journal: Blood (2015)
A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd
Authors: Amin M. Alousi, Rima M Saliba, Julianne Chen, Borje S Andersson, Issa Khouri, Muzaffar H. Qazilbash, Uday R. Popat, Chitra M. Hosing, Stefan O. Ciurea, Elizabeth J Shpall, Roy B. Jones, Partow Kebriaei, Yago Nieto, Paolo Anderlini, Marcos DeLima, Gabriela Rondon, Richard E. Champlin
Journal: Blood (2012)
Cost-Effectiveness of Double-Unit Cord Blood Transplantation Versus Single-Unit Cord Blood Transplantation in Adult Patients with Acute Leukaemia in France- On Behalf of SFGM-TC, Eurocord, ALWP-EBMT
Authors: Myriam Labopin, Annalisa Ruggeri, Namik Taright, Federico Garnier, Catherine Faucher, Anne-Gaelle Le Coroller, Noel-Jean Milpied, Didier Blaise, Manuela Badoglio, Mohamad Mohty, Agnes Buzyn, Fernanda Volt, Eliane Gluckman, Norbert C Gorin, Vanderson Rocha
Journal: Blood (2011)
Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.
Authors: Ingo G.H. Schmidt-Wolf, Hendrik Pels, Annika Juergens, Axel Glasmacher, Holger Schulz, Frank Kroschinsky, Gertlinde Egerer, Monika Lamprecht, Caecilia Wismeth, Uwe Schlegel
Journal: Blood (2006)
Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis
Authors: Richard T. Silver, Elena Lascu, Eric J. Feldman, Ellen Ritchie, Gail J. Roboz, Maria Teresa De Sancho, Ruth Bauman, Attilio Orazi
Journal: Blood (2013)
Dynamics of Bcl-2, Bax and ACE Expression In CD34+ Cells of Peripheral Blood and Bone Marrow In Patients with Acute Leukemia During Induction Therapy
Authors: Elena E. Khodunova, Elena N. Parovichnikova, Irina V. Galtzeva, Sergey M. Kulikov, Valentin G. Isaev, Valeri G. Savchenko
Journal: Blood (2010)
Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline
Authors: Antonio Finelli, Nofisat Ismaila, Bill Bro, Jeremy Durack, Scott Eggener, Andrew Evans, Inderbir Gill, David Graham, William Huang, Michael A.S. Jewett, Sheron Latcha, William Lowrance, Mitchell Rosner, Bobby Shayegan, R. Houston Thompson, Robert Uzzo, Paul Russo
Journal: Journal of Clinical Oncology (2017)

Purpose To provide recommendations for the management options for patients with small renal masses (SRMs). Methods By using a literature search and prospectively defined study selection, we sought systematic reviews, meta-analyses, randomized clinical trials, prospective comparative observational studies, and retrospective studies published from 2000 through 2015. Outcomes included recurrence-free survival, disease-specific survival, and overall survival. Results Eighty-three studies, including 20 systematic reviews and 63 primary studies, met the eligibility criteria and form the evidentiary basis for the guideline recommendations. Recommendations On the basis of tumor-specific findings and competing risks of mortality, all patients with an SRM should be considered for a biopsy when the results may alter management. Active surveillance should be an initial management option for patients who have significant comorbidities and limited life expectancy. Partial nephrectomy (PN) for SRMs is the standard treatment that should be offered to all patients for whom an intervention is indicated and who possess a tumor that is amenable to this approach. Percutaneous thermal ablation should be considered an option if complete ablation can reliably be achieved. Radical nephrectomy for SRMs should only be reserved for patients who possess a tumor of significant complexity that is not amenable to PN or for whom PN may result in unacceptable morbidity even when performed at centers with expertise. Referral to a nephrologist should be considered if chronic kidney disease (estimated glomerular filtration rate &lt; 45 mL/min/1.73 m 2 ) or progressive chronic kidney disease occurs after treatment, especially if associated with proteinuria.
Heparin-Induced Thrombocytopenia
Authors: Gowthami M. Arepally, Thomas L. Ortel
Journal: Annual Review of Medicine (2010)

Heparin-induced thrombocytopenia (HIT) is an immune-mediated hypercoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin. HIT develops in temporal association with heparin therapy and manifests either as an unexplained thrombocytopenia or thrombocytopenia complicated by thrombosis. The propensity for thrombosis distinguishes HIT from other common drug-induced thrombocytopenias. Diagnosing HIT in hospitalized patients is often challenging because of the frequency of heparin use, occurrence of thrombocytopenia from other causes, and development of asymptomatic PF4/heparin antibodies in patients treated with heparin. This review summarizes our current understanding of the pathogenesis, clinical features, diagnostic criteria, and management approaches in HIT.
Thrombopoietin Receptor (MPL) Genotype Modifies the Myeloproliferative Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera.
Authors: Jerry L. Spivak, Donna M Williams, Brady L. Stein, Ophelia Rogers, Tsivia Hochman, Judith D. Goldberg, Wanming Zhao, Zhizhuang Joe Zhao, Alison R Moliterno
Journal: Blood (2009)
Minimal Residual Disease Monitoring after Reduced Intensity Conditioning (RIC) Allogeneic Transplantation: May Help To Individualize Post-Transplant Immunotherapeutic Strategies.
Authors: Maria Diez-Campelo, Jose A. Perez-Simon, Jose J. Perez, Dolores M. Caballero, Belen Vidriales, Miguel Alcoceba, Lourdes Vazquez, Marcos Gonzalez, Consuelo M. Canizo, Consuelo M. Lopez-Berges, Jesus Lopez-Fidalgo D, J.F. San Miguel
Journal: Blood (2005)
Transparency and Trust — Online Patient Reviews of Physicians
Authors: Vivian Lee
Journal: New England Journal of Medicine (2017)

Interview with Dr. Vivian Lee on how physicians and health care systems can get the most out of sharing patient feedback. (12:26)Download With Yelp forcing the issue of publicly available patient ratings of doctors, health care organizations need to consider the goals of transparency efforts, how they can best be achieved, whose responsibility it is, and the best venues for such data sharing.
A Novel Simulation Method for Mapping Dysregulated Pathways and Predicting Effective Therapeutics in the Myelodysplastic Syndromes
Authors: Christopher R. Cogle, Kaoru Tohyama, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Krishna Kumar Tiwari, Anuj Tyagi, Taher Abbasi, Peter P. Sayeski
Journal: Blood (2014)
NK-92 Therapy Is Well Tolerated, Has Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patients with Relapsed/Refractory Hematological Malignancies Relapsing after Autologous Stem Cell Transplantation
Authors: Brent Williams, Bertrand Routy, Neal denHollander, Xing-Hua Wang, Amelie Chaboureau, Sowmya Viswanathan, Armand Keating
Journal: Blood (2015)
Making a song and dance about trachoma
Authors: Richard Hurley
Journal: BMJ (2017)

Children take part in an eye care club at a school in Kedida Gamela, Ethiopia, after a song and dance performance to launch a mass antibiotic administration programme to prevent trachoma. Two in every five children have trachoma in this poor, rural region; without treatment they may lose their sight and face destitution.

The BMJ ’s Christmas appeal for 2016-17 is for the eye care charity Orbis, …
DNA Sequencing of a Murine Acute Promyelocytic Leukemia (APL) Genome Using Next Generation Technology.
Authors: Lukas D. Wartman, Li Ding, David E. Larson, Michael D. McLellan, Heather Schmidt, Zhifu Xiang, Michael Tomasson, Elaine Mardis, Richard K. Wilson, Timothy J. Ley
Journal: Blood (2009)
Monosomal Karyotype in MDS and Secondary AML: Do Autosomal Monosomies Have the Same Poor Prognostic Impact As Monosomy 5 and 7?
Authors: Paolo Bernasconi, Marina Boni, Marianna Rossi, Rita Zappatore, Irene Dambruoso, Paola Maria Cavigliano, Ilaria Giardini, Barbara Rocca, Celeste Calvello, Marilena Caresana, Patrizia Zappasodi, Carlo Castagnola
Journal: Blood (2011)
Identification of Two New DBA Genes, RPS27 and RPL27, by Whole-Exome Sequencing in Diamond-Blackfan Anemia Patients
Authors: Etsuro Ito, Kenichi Yoshida, Yusuke Okuno, Aiko Sato-Otsubo, Tsutomu Toki, Satoru Miyano, Yuichi Shiraishi, Kenichi Chiba, Kiminori Terui, RuNan Wang, Tomohiko Sato, Yuji Iribe, Shouichi Ohga, Madoka Kuramitsu, Isao Hamaguchi, Akira Ohara, Kazuko Kudo, Isamu Kamimaki, Junichi Hara, Kanji Sugita, Kousaku Matsubara, Kenichi Koike, Akira Ishiguro, Yoshifumi Kawano, Hitoshi Kanno, Seiji Kojima, Seishi Ogawa
Journal: Blood (2012)
Methylation and Hydroxymethylation Status of Tumor Suppressor Genes and Common Fragile Sites Genes in Acute Myeloid Leukemia
Authors: Hiroshi Handa, Itsumi Suda, Ayaka Kaneko, Yuta Masuda, Kei Kimura, Yuko Kuroda, Tetsuhiro Kasamatsu, Yusuke Minato, Kenichi Tahara, Hiroaki Shimizu, Takuma Ishizaki, Takeki Mitsui, Akihiko Yokohama, Hiromi Koiso, Makiko Takizawa, Takayuki Saitoh, Naoko Hatsumi, Satoru Takada, Toru Sakura, Norifumi Tsukamoto, Yoshihisa Nojima, Hirokazu Murakami
Journal: Blood (2014)
Myeloma Cells Exhibit Inhibitory Effect On Osteoclastogenesis
Authors: Zhiqiang Liu, Yuhuan Zheng, Haiyan Li, Jingda Xu, Jin He, Eryong Huang, Yong Lu, Jungsun Park, Bangxing Hong, Mingjun Zhang, Jianfei Qian, Pei Lin, Larry W. Kwak, Qing Yi, Jing Yang
Journal: Blood (2012)
Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials.
Authors: Gonzalo Ariel Ferini, Emmanuel Raffoux, Agnès Guerci, Arnaud Pigneux, Françoise Huguet, Norbert Vey, Thierry Lamy, Beatrice Muller, Patrice Chevallier, Sylvie Castaigne, Pascal Turlure, Augustin Ferrant, Norbert Ifrah, Stephane de Botton, Hervé Dombret, Lionel Ades, Pierre Fenaux
Journal: Blood (2010)
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
Authors: Eric J. Duncavage, Geoffrey L. Uy, Allegra A. Petti, Christopher A. Miller, Yi-Shan Lee, Bevan Tandon, Feng Gao, Catrina C. Fronick, Michelle O’Laughlin, Robert S. Fulton, Richard K. Wilson, Meagan A. Jacoby, Amanda F. Cashen, Lukas D. Wartman, Matthew J. Walter, Peter Westervelt, Daniel C. Link, John F. DiPersio, Timothy J. Ley, John S. Welch
Journal: Blood (2017)
MicroRNA Detection Using a Double Molecular Beacon Approach: Distinguishing Between miRNA and Pre-miRNA
Authors: Amanda Marie James, Meredith B. Baker, Gang Bao, Charles D. Searles
Journal: Theranostics (2017)

MicroRNAs (miRNAs) are small, noncoding RNAs that post-transcriptionally regulate gene expression and are recognized for their roles both as modulators of disease progression and as biomarkers of disease activity, including neurological diseases, cancer, and cardiovascular disease (CVD).Commonly, miRNA abundance is assessed using quantitative real-time PCR (qRT-PCR), however, qRT-PCR for miRNA can be labor intensive, time consuming, and may lack specificity for detection of mature versus precursor forms of miRNA.Here, we describe a novel double molecular beacon approach to miRNA assessment that can distinguish and quantify mature versus precursor forms of miRNA in a single assay, an essential feature for use of miRNAs as biomarkers for disease.Using this approach, we found that molecular beacons with DNA or combined locked nucleic acid (LNA)-DNA backbones can detect mature and precursor miRNAs (pre-miRNAs) of low (< 1 nM) abundance in vitro.The double molecular beacon assay was accurate in assessing miRNA abundance in a sample containing a mixed population of mature and precursor miRNAs.In contrast, qRT-PCR and the single molecular beacon assay overestimated miRNA abundance.Additionally, the double molecular beacon assay was less labor intensive than traditional qRT-PCR and had 10-25% increased specificity.Our data suggest that the double molecular beacon-based approach is more precise and specific than previous methods, and has the promise of being the standard for assessing miRNA levels in biological samples.
Gut microbiota: implications for sports and exercise medicine
Authors: Owen Cronin, Orla O'Sullivan, Wiley Barton, Paul D Cotter, Michael G Molloy, Fergus Shanahan
Journal: British Journal of Sports Medicine (2017)

Technological progress in high-throughput sequencing and advanced bioinformatic techniques, have facilitated a deeper understanding of the gut microbial influence on human health. Collectively known as the gut microbiota, the trillions of microbes including bacteria, viruses and fungi, which reside within the gut, are now recognised as significant contributors to human (host) health. Patients with non-communicable diseases such as metabolic syndrome, obesity and inflammatory bowel disease, demonstrate distinct microbial alterations. This has prompted vigorous pursuit of the mechanisms by which this microbial ‘organ’ influences host health. This branch of medicine has already revealed exciting avenues for disease treatment, from the discovery of novel antibiotics to the treatment of recurrent Clostridium difficile infection.1

The scale and spectrum of microbial influence is substantial and elegant studies have linked the presence or absence of specific microbes with immunity,2 neurodevelopment and even behavioural disturbances.3 The potential impact of microbiome science extends to the specialties of Sports Medicine and particularly to Exercise Medicine.

The development of a mature enteric microbiota is subject to modifiable and non-modifiable factors, including diet and host genetics.4 The gut microbiota is perturbed by …
Impact of dermoscopy on an internet-based skin cancer triage system: Interim results of a randomized study
Authors: Lara Ferrándiz, Teresa Ojeda-Vila, Araceli Corrales, Francisco J. Martín-Gutiérrez, Andrés Ruíz-de-Casas, Rafael Galdeano, Ignacio Álvarez-Torralba, Francisco Sánchez-Ibáñez, José M. Domínguez-Toro, Fernando Encina, Francisco J. Narbona, Juan M. Herrerías-Esteban, David Moreno-Ramírez
Journal: Journal of the American Academy of Dermatology (2017)
Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children’s Oncology Group (COG) Study.
Authors: Richard C. Harvey, I-Ming Chen, Kerem Ar, Stephen P. Hunger, Mignon Loh, Eric C. Larsen, Meenakshi Devidas, Elizabeth Raetz, Gregory Reaman, William L. Carroll, Naomi Winick, Malcolm Smith, Kevin K Dobbin, Cheryl L. Willman
Journal: Blood (2008)
The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.
Authors: Roberto Crocchiolo, Sabine Fuerst, Jean El-Cheikh, Angela Granata, Claire Oudin, Geoffroy Venton, Norbert Vey, Reda Bouabdallah, Anne Marie Stoppa, Florence Broussais, Aude Charbonnier, Claude Lemarie, Diane Coso, Thomas Prebet, Christian Chabannon, Didier Blaise
Journal: Blood (2012)
Evi-1 Interacts with Histone Methyltransferases for Transcription Repression and Bone Marrow Transformation.
Authors: Susumu Goyama, Eriko Nitta, Munetake Shimabe, Tetsuya Yoshino, Shinichi Kako, Motoshi Ichikawa, Yoichi Imai, Tsuyoshi Takahashi, Akira Hangaishi, Mineo Kurokawa
Journal: Blood (2008)
Genetic Risk Factors for Folate-Responsive Neural Tube Defects
Authors: Anne M. Molloy, Faith Pangilinan, Lawrence C. Brody
Journal: Annual Review of Nutrition (2017)

Neural tube defects (NTDs) are the most severe congenital malformations of the central nervous system. The etiology is complex, with both genetic and environmental factors having important contributions. Researchers have known for the past two decades that maternal periconceptional use of the B vitamin folic acid can prevent many NTDs. Though this finding is arguably one of the most important recent discoveries in birth defect research, the mechanism by which folic acid exerts this benefit remains unknown. Research to date has focused on the hypothesis that an underlying genetic susceptibility interacts with folate-sensitive metabolic processes at the time of neural tube closure. Little progress has been made searching for risk-causative variants in candidate genes; therefore, more complex genetic and epigenetic methodologies are now being considered. This article reviews the research to date that has been targeted on this important gene-nutrient locus.
ATPS-62TARGETING OF NOVEL GBM BIOMARKER EMP2 RESULTS IN DECREASED TUMOR GROWTH AND INCREASED TUMOR NECROSIS
Authors: Panayiotis Pelargos, Yu Qin, Brittany Voth, Kimberly Thill, Lawrance Chung, Robert Prins, Linda Liau, Nolan Ung, Seyed Hojat, William Yong, Lynn Gordon, Madhuri Wadehra, Isaac Yang
Journal: Neuro-Oncology (2015)

INTRODUCTION: Glioblastoma multiforme (GBM) is a deadly disease with a survival of approximately 15 months. Epithelial membrane protein 2 (EMP2) is correlated with advanced disease and adverse outcomes in several cancers and has recently been found to be expressed on the surface of GBM cells. Its expression in GBM increases integrin surface expression resulting in activation of focal adhesion kinase and Src and promoting increased tumor growth, cell migration, and invasion. METHODS: Subcutaneous and orthotopic mouse models were utilized for this study. In the subcutaneous model, n = 4 BALB/c mice were inoculated with U373 cells and treated with weekly systemic treatments of either anti-EMP2 or control IgG1. Tumor size was measured weekly. In the intracranial model, n = 6 BALB/c nude mice were inoculated with U87 cells overexpressing EMP2 and treated with weekly systemic injections of either anti-EMP2 or control IgG1. Tumor size was followed with bioluminescence imaging. RESULTS: In the subcutaneous model, tumor growth was significantly reduced at 50 days when treated with anti-EMP2 antibody (19 mm3 vs. 45 mm3, p < 0.05), and the residual tumors displayed significant necrosis compared to the control group. In the intracranial model, the treatment group showed a trend toward reduced tumor growth compared to the control group. The mean fold change in average tumor radiance in the treatment group was 402 compared to 543 in the control group. CONCLUSION: Our data present an extremely novel biomarker and therapeutic target for GBM. These findings suggest that targeting EMP2 may be an effective treatment modality for GBM. Further studies are needed to fully elucidate the role of targeting EMP2 in the treatment of GBM.
A Pilot Study of Thrice-Weekly Low Dose Rituximab (RTX) in the Treatment of Chronic Lymphocytic Leukemia (CLL) Suggests Enhanced Therapeutic Targeting Compared to Standard Dose Regimens.
Authors: Ronald P. Taylor, Andrew W. Pawluczkowycz, Paul V. Beum, Adam D. Kennedy, Margaret A. Lindorfer, John J. Densmore, Jane Eggleton, Karen L. LoRusso, Michael E. Williams
Journal: Blood (2004)
Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone
Authors: Jenny Pena Dias, Johannes D. Veldhuis, Olga Carlson, Michelle Shardell, Chee W. Chia, Denise Melvin, Josephine M. Egan, Shehzad Basaria
Journal: Metabolism (2017)
Bestrophinopathy: An RPE-photoreceptor interface disease
Authors: Karina E. Guziewicz, Divya Sinha, Néstor M. Gómez, Kathryn Zorych, Emily V. Dutrow, Anuradha Dhingra, Robert F. Mullins, Edwin M. Stone, David M. Gamm, Kathleen Boesze-Battaglia, Gustavo D. Aguirre
Journal: Progress in Retinal and Eye Research (2017)
Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.
Authors: Ferdinando Frigeri, Gaetano Corazzelli, Manuela Arcamone, Gaetana Capobianco, Anna Lucania, Cristina Becchimanzi, Gianpaolo Marcacci, Filippo Russo, Maria Rosaria Villa, Lucia Mastrullo, Antonio Pinto
Journal: Blood (2009)
An Effective Salvage Treatment Using Rituximab, Ifosfamide, Etoposide, Cytarabine, and Dexamethasone (R-IVAD) for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
Authors: Katsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi, Yujin Kobayashi, Toshitake Tanaka, Daisuke Kurita, Noriyoshi Iriyama, Yasuyuki Inoue, Yoshihiro Hatta, Yoshimasa Kura, Umihiko Sawada, Jin Takeuchi
Journal: Blood (2010)